[go: up one dir, main page]

WO2002007760A3 - Therapeutic agent against aids comprising anti hiv goat antibody - Google Patents

Therapeutic agent against aids comprising anti hiv goat antibody Download PDF

Info

Publication number
WO2002007760A3
WO2002007760A3 PCT/GB2001/003292 GB0103292W WO0207760A3 WO 2002007760 A3 WO2002007760 A3 WO 2002007760A3 GB 0103292 W GB0103292 W GB 0103292W WO 0207760 A3 WO0207760 A3 WO 0207760A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
agent against
goat antibody
anti hiv
against aids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2001/003292
Other languages
French (fr)
Other versions
WO2002007760A2 (en
Inventor
Gary Davis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICE Biologics Ltd
Original Assignee
ICE Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICE Biologics Ltd filed Critical ICE Biologics Ltd
Priority to AU2001275696A priority Critical patent/AU2001275696A1/en
Publication of WO2002007760A2 publication Critical patent/WO2002007760A2/en
Publication of WO2002007760A3 publication Critical patent/WO2002007760A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A composition is provided for the treatment of HIV and AIDS, the composition comprising antibody of a goat after challenge with a human HIV virus, and a method for treatment of a human infected with the HIV virus comprising administration of the antibody to the infected individual.
PCT/GB2001/003292 2000-07-21 2001-07-20 Therapeutic agent against aids comprising anti hiv goat antibody Ceased WO2002007760A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001275696A AU2001275696A1 (en) 2000-07-21 2001-07-20 Therapeutic agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21991000P 2000-07-21 2000-07-21
US60/219,910 2000-07-21

Publications (2)

Publication Number Publication Date
WO2002007760A2 WO2002007760A2 (en) 2002-01-31
WO2002007760A3 true WO2002007760A3 (en) 2002-04-18

Family

ID=22821237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/003292 Ceased WO2002007760A2 (en) 2000-07-21 2001-07-20 Therapeutic agent against aids comprising anti hiv goat antibody

Country Status (2)

Country Link
AU (1) AU2001275696A1 (en)
WO (1) WO2002007760A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064472A2 (en) * 2002-01-28 2003-08-07 Aimsco Limited Treatment of ms with goat serum
BR0210772A (en) * 2001-07-02 2004-07-20 Aimsco Ltd Uses of an anti-hla antibody, and a goat serum composition
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
GB0600202D0 (en) * 2006-01-06 2006-02-15 Aimsco Ltd Treatment of HIV
US20180235900A1 (en) * 2017-02-06 2018-08-23 Research Triangle Institute Subcutaneous reservoir device and method of manufacture

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016710A1 (en) * 1993-12-13 1995-06-22 United Biomedical, Inc. Specific hyperimmune anti-hiv globulin for passive immunization
WO1997002839A1 (en) * 1995-07-13 1997-01-30 Gkc Research, Inc. Viral suppression, treatment and prevention of viral infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016710A1 (en) * 1993-12-13 1995-06-22 United Biomedical, Inc. Specific hyperimmune anti-hiv globulin for passive immunization
WO1997002839A1 (en) * 1995-07-13 1997-01-30 Gkc Research, Inc. Viral suppression, treatment and prevention of viral infections

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KARPAS A ET AL: "Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 85, no. 23, December 1988 (1988-12-01), pages 9234 - 9237, XP002158689, ISSN: 0027-8424 *
KUDOYAROVA-ZUBAVICHENE N M ET AL: "PREPARATION AND USE OF HYPERIMMUNE SERUM FOR PROPHYLAXIS AND THERAPY OF EBOLA VIRUS INFECTIONS", JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 179, no. SUPPL 1, February 1999 (1999-02-01), pages S218 - S223, XP000979167, ISSN: 0022-1899 *
PALKER T ET AL: "Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 142, no. 10, 15 May 1989 (1989-05-15), pages 3612 - 3619, XP002158688, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
AU2001275696A1 (en) 2002-02-05
WO2002007760A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO2003051306A3 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
EE05442B1 (en) A low dose entecavir pharmaceutical composition for the treatment of hepatitis B virus infection and a method for its preparation
WO2001095899A3 (en) Pharmaceutical compositions comprising cannabidiol derivatives
TW371628B (en) Composition for treating condyloma acuminata
EA200201263A1 (en) METHODS OF TREATING INFECTIONS, CAUSED BY THE HEPATITIS DELTA VIRUS, USING β-L-2'-DEOXYNUCLEOSIDES
WO2002000242A8 (en) Human papilloma virus treatment
NZ515392A (en) Respiratory syncytial virus replication inhibitors
WO2004107956A3 (en) Methods and devices for the treatment of skin lesions
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
WO2002028426A8 (en) Split enveloped virus preparation
AU1167602A (en) Methods of therapy for hiv infection
WO2003059385A3 (en) Hiv vaccine and method of use
WO2004026260A3 (en) Prophylactic and therapeutic hiv aptamers
WO2001055111A8 (en) Biaryl compounds, their preparation and their use in therapy
WO2003004049A3 (en) Use of polyclonal anti-hiv goat serum as a therapeutic agent
CA2504872A1 (en) Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2006044968A3 (en) Combination therapy for treating viral infections
WO2002007760A3 (en) Therapeutic agent against aids comprising anti hiv goat antibody
AU2003217604A8 (en) Method of treating hiv infection by preventing interaction of cd4 and gp120
WO2005097618A3 (en) Low dose therapy for treating viral infections
IL236509A0 (en) Use of one or more HBV antigens for the preparation of oral pharmaceutical preparations for the treatment of a person with active HBV infection or hepatocellular carcinoma
WO2005089231A3 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
AU2001233063A1 (en) Vaccination of hiv infected persons following highly active antiretroviral therapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP